---
title: 'Overall Survival From Tebentafusp Versus Nivolumab Plus Ipilimumab in First
  Line Metastatic Uveal Melanoma: A Propensity Score Weighted Analysis'
date: '2023-12-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38048850/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231205170740&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Tebentafusp was previously shown to provide an OS benefit
  compared to checkpoint inhibitors or chemotherapy in untreated mUM. Propensity score
  analysis demonstrated a similar OS benefit for tebentafusp compared with N+I. These
  data further support tebentafusp as the standard of care in previously untreated
  HLA-A*02:01+ adult patients with ...'
disable_comments: true
---
CONCLUSION: Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM. Propensity score analysis demonstrated a similar OS benefit for tebentafusp compared with N+I. These data further support tebentafusp as the standard of care in previously untreated HLA-A*02:01+ adult patients with ...